| Name | Title | Contact Details |
|---|
Hanson Research is a Chatsworth, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
COMPASS is a mental health care company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.
Sinoveda is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are Salience Learning. We help solve life science’s most complex business challenges by delivering transformative learning experiences.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.